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Abstract: Androgens play a key role in the control of spermatogenesis and interference with their intratesticular secretion and action is a 
critical element in many contraceptive strategies. Nonetheless, the cellular and molecular mechanisms by which androgens control germ 
cell development remain poorly understood. Recent transgenic models in which the androgen receptor (AR) is selectively ablated in Ser-
toli cells show unambiguously that the Sertoli cell is the main target for androgen action in the control of spermatogenesis. A number of 
additional mouse models have been developed mimicking human diseases in which mutations of the AR cause disturbed fertility without 
affecting male development. Transcriptional profiling studies in mice with Sertoli cell-selective AR ablation and in some other experi-
mental paradigms have tried to identify androgen-regulated genes relevant to the control of spermatogenesis. The overlap in genes identi-
fied in different studies is poor but this may be due mainly to dissimilarities in experimental setup. In all studies, relatively large numbers 
of genes rather than a few key genes seem to be affected by androgen action. Genes related to tubular restructuring, cell junction dynam-
ics, cytoskeleton, solute transportation and vitamin A metabolism are prominently present. Although further work is obviously needed, it 
may be anticipated that these studies will result in the identification of subsets of genes that can be used as diagnostic tools as well as in 
the identification of targets for the development of novel contraceptives.  
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1. INTRODUCTION 
 The pituitary gonadotropins FSH and LH control both the onset 
and maintenance of spermatogenesis and male reproductive func-
tion [1-3]. Their secretion is tightly controlled by central regulators 
such as hypothalamic GnRH and by testicular feedback signals 
including the steroid hormones testosterone and 17-estradiol and 
the peptide hormone inhibin B. Most efforts to develop pharmacol-
ogical methods of male contraception have aimed at manipulating 
gonadotropin secretion with consequent suppression of intratesticu-
lar testosterone levels [4-6]. These efforts have now provided a firm 
base to develop an acceptable male contraceptive, but it is obvious 
that further improvements are needed and that alternative ap-
proaches should be considered. Progress in this area will critically 
depend on a better understanding of the cellular and molecular 
mechanisms by which gonadotropins, and especially testosterone, 
secreted by the Leydig cells under the influence of LH, control 
spermatogenesis. Such an understanding may: 1) help to explain the 
important inter-racial and inter-individual variability in the effi-
ciency of presently available male contraceptive protocols that rely 
on suppression of intratesticular testosterone; 2) point to key events 
in the control of germ cell development that may represent novel 
targets for pharmacological interference and 3) help to develop 
compounds that more selectively interfere with testicular targets of 
androgen action. In this review we will focus on recent progress in 
our understanding of the mechanisms by which testicular androgens 
affect spermatogenesis. 
2. ANDROGENS ARE KEY REGULATORS IN THE CON-
TROL OF SPERMATOGENESIS 
 There is an overwhelming amount of evidence showing that 
optimal spermatogenesis requires both LH and FSH. The relative 
role of these gonadotropins, however, may vary from species to  
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species and may differ whether initiation, maintenance or re-
initiation of spermatogenesis is considered [1-3]. 
 FSH affects spermatogenesis via the Sertoli cells which are 
widely accepted to be the only cells in the testis endowed with FSH 
receptors [7, 8]. FSH plays a very important role in pre- and pe-
ripubertal Sertoli cell proliferation [9] and in this way it is a key 
determinant of spermatogenic capacity in adult life [2, 10]. Fur-
thermore it has important effects on the proliferation and differen-
tiation of spermatogonia and on the process of spermiation [11-13]. 
In general, FSH may play a more prominent role in primates and in 
man than in rats and mice [1-3]. 
 LH acts on the Leydig cells to increase the secretion of testos-
terone. This results in the high intratesticular concentrations of 
testosterone that are apparently required to initiate and maintain 
spermatogenesis [2]. The circulating levels of testosterone are about 
20-100 times lower than those measured in the testis but are obvi-
ously adequate for male sexual differentiation, stimulation of acces-
sory sex glands, sexual behavior and hypothalamo-pituitary feed-
back. Testosterone plays a key role in the control of spermatogene-
sis. Only a few years after the discovery of the role of the pituitary 
in the maintenance of spermatogenesis [14] and of the distinct func-
tions of LH and FSH [15] it was already shown that high amounts 
of exogenous androgens were able to substitute at least in part for 
the pituitary gland and to maintain qualitatively normal spermato-
genesis in hypophysectomized mice [16] and monkeys [17]. Since 
then the ability of testosterone to initiate, maintain, or reinitiate 
spermatogenesis in the absence or in the virtual absence of FSH has 
been confirmed in a variety of species and by the use of a whole 
spectrum of experimental paradigms including intact and hypophy-
sectomized animals, animals treated with GnRH agonists or an-
tagonists, with FSH antisera or with the Leydig cell toxicant ethane 
dimethane sulphonate (for review [2]). 
 A number of recent genetic models nicely confirm the unique 
ability of testosterone to support some degree of spermatogenesis 
on its own. In mice that are hypogonadal due to a large deletion in 
the GnRH gene (hpg mice), for instance, administration of testos-
terone restores qualitatively complete spermatogenesis [18, 19].  
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Conversely, fertility is maintained in man and mice with inactivat-
ing mutations of the FSH receptor gene [20-22] and in mice that are 
unable to synthesize FSH [23]. 
 A vast amount of experimental work has been done to define 
the exact stages at which androgens, alone or in collaboration with 
FSH, affect germ cell development. In rodents a series of events 
centered about stage VII and VIII of the spermatogenic cycle seem 
particularly sensitive to hormonal disruption [2, 24-26]. Interest-
ingly (see further) these are also the stages at which the concentra-
tion of the AR in Sertoli cells reaches maximal levels [27, 28]. 
Processes that are particularly sensitive to androgen action are Ser-
toli cell adherence of round spermatids, which is essential for fur-
ther development into elongated spermatids [2, 3, 29-33], and 
spermiation [12, 34, 35]. Also progression through meiosis strictly 
depends on androgen action (see below). Surprisingly, high concen-
trations of androgens negatively affect spermatogonial differentia-
tion in specific models in which only the early steps of spermato-
genesis are present, such as irradiated rats or jsd mice at normal 
scrotal temperature [36, 37]. 
3. ANDROGEN SIGNALING VIA CLASSICAL AND AL-
TERNATIVE PATHWAYS 
 The cellular and molecular mechanisms involved in the control 
of spermatogenesis by androgens remain poorly understood. An-
drogens are steroid hormones and their actions are largely mediated 
by a “classical” or genomic pathway shared by all steroid hor-
mones. Central to this pathway is a specific receptor, the androgen 
receptor (AR), a member of the large family of ligand-activated 
nuclear receptors. The AR is encoded by a single gene, 75-90 kb 
long and located on the long arm of the X chromosome [38, 39]. 
The 110-kDa AR protein displays a modular structure resembling 
that of other steroid receptors and characterized by: an aminotermi-
nal domain involved in transcription activation, a central DNA-
binding domain featuring two zinc-fingers, a hinge region and a 
carboxyterminal domain responsible for ligand recognition and, via 
interaction with the aminoterminal domain, also for transcription 
activation. A specific feature of the aminoterminal domain of the 
human AR is the presence of a CAG/polyglutamine repeat of vari-
able length (average: 21 ± 2) that affects its inherent biological 
activity [40, 41]. Although the data are somewhat controversial 
there are several indications that higher repeat lengths may lower 
androgen responsiveness, decrease sperm concentrations and in-
crease effectiveness of hormonal contraception in men in which 
gonadotropin suppression is incomplete (for review [42]). Very 
large repeat lengths (> 37) result in a slowly progressive neurode-
generative disease characterized by flaccid proximal paralysis and 
muscle atrophy (spinobulbar muscular atrophy (SBMA) or Ken-
nedy’s disease) and also by signs of androgen insensitivity such as 
gynecomastia and progressive infertility [43]. The disease is proba-
bly caused by the formation of toxic complexes of the mutated AR 
allele with other proteins [44]. 
 A detailed discussion of the mechanism(s) of androgen action is 
beyond the scope of the present review. We will only summarize 
the major events in the AR signaling cascade and mention some 
aspects that are either typical for androgen action and/or specifi-
cally relevant to the process of spermatogenesis. Activation of the 
AR occurs classically by the binding of natural ligands (testoster-
one, 5-dihydrotestosterone) or synthetic ligands with agonistic 
effects. This activation is followed by nuclear translocation, in-
creased phosphorylation and subsequent interaction of the AR as a 
homodimer with specific recognition sequences known as AREs 
(Androgen Response Elements) [38, 39, 45, 46]. These AREs are 
located in the regulatory regions of androgen-responsive genes. 
Their structure shows an important degree of variability. “Classi-
cal” AREs are inverted partial repeats of 5’-TGTTCT-3’-like se-
quences separated by 3 nucleotides. They act not only as ARE but 
also as GRE and PRE (Glucocorticoid/Progesterone Response Ele-
ment). Apart from these classical promiscuous AREs, however, 
there also exist “selective” AREs that do not recognize the GR. 
They are organized as direct rather than inverted repeats of 5’-
TGTTCT-3’-like sequences and display an alternative binding 
mode to the AR [47]. Binding of the AR to the DNA ultimately 
results in the recruitment of coactivators, corepressors and other 
regulatory molecules or mediators which induce structural altera-
tions in the chromatin and facilitate direct and indirect interactions 
with the transcription initiation complex [48, 49]. Both the nature of 
the AREs and the nature of the coregulatory molecules are impor-
tant determinants of the spectrum of genes that is ultimately acti-
vated or inactivated. A specific coactivator known as transcription 
intermediary factor 2 (TIF-2) may serve as the preferential coacti-
vator of the AR in testicular Sertoli cells [50, 51]. 
 A specific feature of androgen action is the important role 
played by so called “active metabolites”. At least two active me-
tabolites complement the spectrum of effects induced by the main 
circulating androgen: testosterone. In a variety of target tissues 5-
reduction of testosterone results in the formation of 5-dihydrotes-
tosterone (DHT) a more potent androgen that binds to the same AR 
[52, 53]. This conversion may be catalyzed by one of two distinct 
5-reductases (referred to as type 1 and type 2) [54]. Some andro-
gen effects depend entirely on the ability of particular target tissues 
to produce DHT, as illustrated by a specific form of male pseudo-
hermaphroditism observed in patients with an absence of the 5-
reductase, type 2 and characterized by normal internal male genital 
structures and defective external virilisation [55]. Alternatively, 
testosterone may be converted by aromatization into 17-estradiol. 
which will then act via its cognate receptors the estrogen receptors 
 or  (ER and ER) [52, 56]. Again, animals and patients with 
defective aromatase activity or absence of one of the ERs illustrate 
the essential role played by this active metabolite for some of the 
actions of testosterone on bone and on fertility [57]. 
 Apart from these classical “genomic” pathways there probably 
exist “alternative” signaling pathways that may or may not involve 
the classical AR and that may explain some specific and/or ex-
tremely rapid effects [58]. Testosterone has been shown for in-
stance to induce rapid increases in intracellular calcium in isolated 
Sertoli cells. These effects are counteracted by the anti-androgen 
hydroxyflutamide suggesting involvement of the AR [59]. Simi-
larly, evidence has been presented that testosterone activates mito-
gen-activated protein kinase (MAPK) and cAMP response element-
binding protein (CREB) via Src kinase and the epidermal growth 
factor receptor in Sertoli cells, an action that may involve a popula-
tion of AR localized to the plasma membrane [60, 61]. The physio-
logical role of these alternative signaling pathways is poorly under-
stood but certainly merits further investigation, given the fact that 
quantitatively normal spermatogenesis seems to require concentra-
tions of androgens higher than those required to saturate the AR. 
4. FUNDAMENTAL QUESTIONS ABOUT ANDROGEN AC-
TION IN THE TESTIS REMAIN UNANSWERED 
 There is an overwhelming amount of data showing that defects 
in testicular androgen production, whether occurring spontaneously, 
or induced (for instance by contraceptive methods involving the 
administration of androgens and/or progestagens) disturb fertility 
[4-6, 42]. There is also increasing evidence that defects in androgen 
signaling may have major effects on germ cell production [38, 42]. 
In some of the latter defects, the disturbed fertility is due to major 
derangements in sexual differentiation and/or aberrant location of 
the testis. In others, however, including some specific point muta-
tions of the AR, infertility is the main or only clinical feature [38, 
42]. Despite all this, we are still far away from a detailed under-
standing of how androgens act in the testis. Several fundamental 
questions remain unanswered: 1) What is the relative contribution 
of various testicular cells to the control of spermatogenesis? 2) Why 
does normal spermatogenesis apparently require concentrations of 
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androgens that are higher than those needed to saturate the AR? 3) 
What is the role of active metabolites such as DHT and 17-
estradiol? 4) What are the molecular pathways via which androgens 
control germ cell proliferation and development?  
 Here we will focus on the identification of the cells responsible 
for the control of spermatogenesis by androgens and particularly on 
some recently developed transgenic models that are relevant to this 
question and that may aid in identification of the molecular path-
ways involved.  
5. IDENTIFICATION OF THE SERTOLI CELL AS THE 
MAIN TARGET FOR ANDROGEN ACTION IN THE CON-
TROL OF SPERMATOGENESIS 
 It is unlikely that germ cells themselves serve as a direct target 
for androgen action in the testis. Though not all studies consent 
[62], one recent study suggests that fetal germ cells express the AR 
and are targets for androgens that physiologically inhibit their pro-
liferation [63]. Most studies agree that adult germ cells do not ex-
press the AR [28, 64]. Furthermore, expression of the AR in germ 
cells is apparently not required for germ cell development. Germ 
cells in which the AR is defective develop normally when they are 
supported by AR-positive Sertoli cells [65, 66] and mice with a 
germ cell specific AR knockout display normal fertility [67]. The 
only possibility that cannot be excluded is that androgens might 
affect germ cells via one of the mentioned alternative pathways that 
do not involve the AR. 
 The main AR-positive cells in the testis are somatic cells such 
as Sertoli cells, peritubular myoid cells and Leydig cells [28, 68, 
69]. Given their intimate morphological and functional interactions 
with developing germ cells, Sertoli cells are generally considered 
prime candidates as mediators of androgen effects on spermato-
genesis.  
5.1. The In Vitro Approach: Isolated and Cultured Sertoli Cells 
 Despite the fact that isolated and cultured Sertoli cells express 
the AR, attempts to study androgen action in such cultures have 
yielded rather disappointing results. Only a limited number of 
genes, proteins or activities have been identified that are allegedly 
regulated by androgens in primary cultures of Sertoli cells (Table 1) 
[4]. Moreover, the amplitude of the observed effects is limited and 
for some of the effects doubt has been raised about the nature of the 
underlying mechanisms [70]. Part of the stimulatory effects of an-
drogens on ABP production and secretion for instance may be re-
lated to ligand-induced protein stabilization [71]. Similarly, the 
stimulatory effects of androgens on Sertoli cell transferrin secretion 
[72, 73] and the inhibitory effects on FSH-induced aromatase activ-
ity [74] may largely be mediated by androgen-controlled paracrine 
factors - usually referred to as P-Mod-S (Peritubular factors that 
Modulate Sertoli cell function) - secreted by contaminating peritu-
bular myoid cells [75-78]. A number of additional androgen-
regulated proteins produced by Sertoli cells have been identified by 
anion exchange high-performance liquid chromatography or 2D-gel 
electrophoresis [79-81] but most of them are low abundance pro-
teins and/or have not been studied in more detail.  
 Studies with immortalized Sertoli cell lines have been equally 
disappointing [82]. The widely used TM4 line was originally re-
ported to be AR-positive but has proven of little help in the identifi-
cation of androgen-regulated genes with the possible exception of a 
78 kD glucose-regulated protein [83]. Similarly, in MSC-1 cells 
induction of the androgen-responsive Rhox5 gene (see below) 
could be demonstrated but only after cotransfection with an AR 
expression construct [84]. An SK11 cell line which has recently 
been shown to be AR-positive and capable of driving an ARE re-
porter gene [85] may hold promise for further investigation.  
 The fact that primary cultures of Sertoli cells and Sertoli cell 
lines have been of limited help in the identification of genes af-
fected by androgen signaling can probably be explained by a rela-
tively important loss of differentiated function. This loss of function 
is nicely illustrated by the failure of these cells to express Rhox5 
(Reproductive homeobox on the X chromosome 5, earlier referred 
to as Pem). Rhox5 is a homeobox gene, specifically expressed in 
Sertoli cells and epididymal cells in vivo [84, 86] and widely used 
as a lead gene in the search for androgen effects on Sertoli cells. In 
vivo its expression is stimulated up to 50-fold by androgens during 
the development of the mouse testis [86]. In isolated Sertoli cells, 
however, Rhox5 expression drops to undetectable levels within the 
first 24 hours of culture [87]. A specific feature of this loss of dif-
ferentiated function may be a reduction in androgen responsiveness. 
Although cultured Sertoli cells express measurable levels of AR 
[69, 71], attempts to demonstrate androgen responsiveness by use 
Table 1. Genes, Proteins or Activities Regulated by Androgens in Isolated Sertoli Cells 
Parameter Assay Response Species References 
Androgen Binding Protein (ABP) protein  rat [71, 72, 115, 142] 
Transferrin protein +mRNA  rat [72, 73] 
Testibumin (CMB-1) protein  rat [143] 
Testins (CMB22, CMB23) protein  rat [144] 
N-Cadherin protein  rat [145, 146]* 
FSH-induced aromatase activity  rat [74] 
Plasminogen activator activity  rat [147] 
Glutathion S-transferase  protein +mRNA  pig [148] 
UDP-glucuronosyl transferase 1 A1 & B1 mRNA  rat [149] 
c-Myc mRNA  rat [150] 
Claudin 11 mRNA 
protein+mRNA 
 
 
mouse 
rat 
[151] 
[152] 
Ornithine decarboxylase protein+mRNA  rat [153] 
TGF-1 mRNA  pig [154] 
*only in the presence of FSH and in immature Sertoli cells 
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of transfected androgen-responsive promoter-reporter constructs 
have yielded equivocal results. In one study with low transfection 
efficiency, induction mediated by the endogenous AR could be 
demonstrated [88]. In a subsequent study with a much higher trans-
fection efficiency no induction was seen for three different pro-
moter-reporter constructs even after doubling of the endogenous 
AR concentration by pretreatment with FSH [89]. In the latter study 
marked induction was observed, however, after cotransfection with 
an AR expression construct suggesting that AR concentration is a 
limiting factor. In fact, several data indicate that androgen respon-
siveness of Sertoli cells may vary considerably depending on their 
specific environment and may be modulated not only by hormones 
including androgens themselves and FSH [71], but also by 
paracrine factors such as P-Mod-S [62, 75, 90] and by signals gen-
erated by the associated complement of germ cells [62, 91]. The 
latter point is illustrated by the marked changes in AR concentra-
tion during the cycle of spermatogenesis and the fact that the high-
est concentrations of AR are noted at those stages (stage VII and 
VIII) that are also most dependent on androgen action [27, 28]. It is 
tempting to speculate that in a system where the AR may be con-
tinuously saturated by the high local concentrations of testosterone, 
variations in AR concentration and androgen responsiveness may 
be an important way to allow modulation of androgen action.  
5.2. The In Vivo Approach: Sertoli Cell-Selective Knockout of 
the AR  
 The described findings point to the need to study androgen 
action in Sertoli cells under conditions that preserve their microen-
vironment including their interactions with surrounding testicular 
cells. Mice in which the AR is selectively ablated in Sertoli cells 
offer an experimental paradigm that may meet these requirements.  
 Cell-selective knockouts can be generated by a technology 
(Cre/LoxP) that exploits the ability of the Cre recombinase (derived 
from bacteriophage P1) to mediate efficient site-specific recombi-
nation between 34 bp recognition sites known as loxP sites [92]. 
The use of this technology depends upon the development of two 
transgenic mouse strains: one in which a critical region of the tar-
geted gene (e.g. the AR) is “floxed” (by insertion of a loxP site at 
its 5’-upstream and its 3’-downstream end) and one that expresses 
the Cre recombinase in a cell-selective fashion (or ubiquitously). 
When both loxP sites are oriented in the same direction, the Cre 
recombinase will remove the floxed region, when the sites are in 
opposite orientation it will invert the floxed region. At present three 
transgenic models with a Sertoli cell-selective knockout of the AR 
have been developed (Fig. 1 A-C) [68, 93, 94]. We will discuss in 
some detail the SCARKO (Sertoli Cell-selective AR KnockOut) 
model developed in our laboratory and compare its phenotype with 
that of the two other Sertoli cell-selective knockouts: the S-AR
-/y 
mouse and the Ar
flox(ex1-neo)/Y
; AMH-Cre mouse.  
5.2.1. The SCARKO Model 
 SCARKO mice were produced by crossing females carrying an 
AR allele with a floxed exon 2 (AR
flox
) with males expressing the 
Cre recombinase under the control of the Anti-Müllerian Hormone 
promoter (AMH-Cre) [68]. Exon 2 encodes the crucial first zinc 
finger of the AR DNA-binding domain and its deletion provokes a 
frame shift and premature termination of the AR transcript [95]. 
The AMH-Cre construct drives expression of the Cre recombinase 
selectively in Sertoli cells from day 15 postcoitum onwards [96]. 
For comparative purposes mice with a ubiquitous AR knockout 
(ARKO) were also produced by crossing the same AR
flox
 females 
with males expressing the Cre recombinase ubiquitously from early 
zygote stage onwards under control of the phosphoglycerate kinase 
promoter [97]. Table 2 summarizes the main features of the 
SCARKO mouse and compares them with those of the ARKO, the 
AR
flox
 and those of another mouse model expressing a mutated AR 
and to be discussed later: the SPARKI.  
 Since the construction of a floxed AR modifies the wild-type 
AR gene it is essential to show that these modifications as such do 
not affect AR function. Table 2 confirms that this is the case for the 
AR
flox
 developed in our laboratory. Testis weight at day 50 is 
slightly decreased but this difference is not noted at day 140 (data 
not shown) and all other parameters studied are normal. The pheno-
type of the ARKO reflects a complete androgen insensitivity syn-
drome and confirms that the Cre/loxP system is working properly. 
ARKO males are undistinguishable from normal female littermates 
and show a female growth curve. Their testes are very small and 
located intra-abdominally. Wolffian duct derivatives such as epidi-
dymides, deferent ducts and seminal vesicles are absent. Spermato-
genesis is severely disturbed but the cryptorchid position of the 
testes obscures the contribution of defective androgen action in the 
observed defect. LH production is markedly increased reflecting 
both defective Leydig cell function [98] and disturbed androgen-
mediated negative feedback. The ARKO phenotype is essentially 
identical to that of mice with a spontaneous inactivation of the AR 
(Tfm mice) [99] and to that of mice with ubiquitous excisions of the 
AR exon 1 [93, 100], exon 2 [101] or exon 3 [102], generated in 
other laboratories.  
 SCARKO mice show a completely different and unique pheno-
type. They are undistinguishable from wild-type males, have nor-
mally developed internal male genital tracts and show a male 
growth curve. The testes are normally descended in the scrotum and 
are larger than those of the ARKO, but are still markedly reduced in 
size in adulthood (28% of wild-type). Immunohistochemistry con-
firms complete absence of AR staining in Sertoli cells whereas 
staining in Leydig cells and peritubular cells is nicely preserved. 
Absence of a functional AR selectively in Sertoli cells is further 
confirmed by quantitative RT-PCR as well as immunohistochemis-
try showing absence of Rhox5 mRNA and protein expression in 
Sertoli cells whereas expression in the epididymis is preserved.  
 Stereological analysis reveals that the number of Sertoli cells 
(as estimated from Sertoli cell nuclear volume) is identical in 
SCARKO and control testes [103]. This is in contrast to animals 
with a ubiquitous ablation of the AR [100] which show a progres-
sive decline in the number of Sertoli cells from day 2 onwards 
[103-105]. Since this decrease can apparently not be explained by 
the intra-abdominal location of the testes [104], these findings sug-
gest that androgens affect Sertoli cell number during early devel-
opment by a pathway that does not involve the Sertoli cell AR. It is 
tempting to speculate that androgen signaling via peritubular myoid 
cells may be responsible. Along the same lines, some key develop-
mental processes in Sertoli cells such as the prepubertal decline in 
AMH expression, the acute increase in the expression of p27
kip1
 and 
GATA1 at around the time of Sertoli cell maturation and the pro-
gressive increase in sulphated glycoprotein 2 with maturation, all 
seem to proceed normally in the SCARKO and even in the ARKO 
testis [103], suggesting their non-dependence-on a functional Ser-
toli cell AR .  
 Despite all this, Sertoli cells in the SCARKO testis are obvi-
ously functionally defective and unable to support spermatogenesis. 
Concordant with the reduction in testicular volume there is a 
marked decrease in tubular diameter and in tubular lumen size 
probably reflecting a defect in secretory function, a process known 
to be dependent on androgen action [106]. Moreover, stereological 
analysis reveals that the number of spermatogonia is preserved in 
the SCARKO testis but that the number of spermatocytes, round 
spermatids and elongated spermatids is reduced to 64%, 3% and 0% 
of wild-type respectively [68, 103]. This apparent block in meiosis 
is confirmed by the reduced expression of typical meiotic genes 
such as SCP-3 and Spo-11 and the absence of expression of post-
meiotic genes such as transition proteins and protamines. The ab-
sence of round spermatids cannot be explained by premature 
sloughing from the epithelium, as no round spermatids are observed 
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in the epididymis, but is apparently due to a 5-fold increase in the 
number of apoptotic germ cells [68].  
 Interestingly, selective ablation of the AR in Sertoli cells also 
affects Leydig cell development and function. In the adult 
SCARKO testis the number of Leydig cells is reduced by about 
50% but Leydig cell volume is increased by 25% and expression of 
steroidogenic enzymes is also increased [107]. Seminal vesicle 
weight and serum testosterone levels are undistinguishable from 
those of control littermates and LH levels tend to be slightly in-
creased although not statistically significant. 
5.2.2. Other Sertoli Cell-Selective Knockouts 
 Two other Sertoli-cell selective knockout models have been 
reported. The first one (S-AR
-/y
) also relies on the excision of the 
AR exon 2 and uses the same AMH-Cre expressing mouse strain 
utilized in the development of the SCARKO (Fig. 1B) [94]. The 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of discussed mutant androgen receptor (AR) alleles. A. The first 3 exons (red arrows) of the wild-type AR (WT AR allele). 
B. AR with a floxed exon 2 (ARflox). The loxP sites (blue arrowheads) are oriented in the same direction. Female mice carrying the ARflox are crossed with 
male mice expressing the Cre recombinase selectively in Sertoli cells under control of the Anti-Müllerian Hormone promoter (AMH-Cre) to generate male 
mice with a Sertoli cell-selective AR knockout (SCARKO or S-AR-/y) by excision of the AR exon 2. C. AR allele in which exon 1 is floxed by 2 loxP sites 
oriented in opposite direction (Arflox(ex1-neo)). A neomycin selection cassette (neo) in intron 1, used in the generation of mice carrying the allele is not removed. 
The crossing of female mice carrying the Arflox(ex1-neo) allele with male AMH-Cre mice generates males in which the AR is selectively inactivated in Sertoli 
cells by inversion of the floxed exon 1 (Arflox(ex1-neo)/Y; AMH-Cre). D. Homologous recombination of exon 3 of the WT AR with exon 4 of the GR results in an 
AR allele in which the region encoding the second zinc-finger of the DNA-binding domain of the AR is replaced by the corresponding region of the GR. This 
SPARKI allele (Specificity-Affecting AR KnockIn) encodes an AR that is still able to bind classical (non-selective) AREs but is no longer able to bind and 
activate genes driven by a selective ARE. 
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phenotype of these animals strongly resembles that of the 
SCARKO. The main difference is apparently that S-AR
-/y
 males 
show hypotestosteronemia and a 4.5-fold increase in LH levels. 
This slightly different phenotype can probably be explained by 
minor technical differences and/or differences in genetic back-
ground. Considerably more important discrepancies are observed 
with the second model in which exon 1 is the targeted region of the 
AR and in which this exon is floxed by two loxP sites oriented in 
opposite direction (Fig. 1C) [93]. In this case the floxed males (Ar-
flox(ex1-neo)/Y
) already display reduced AR levels and a hypomorphic 
phenotype due to the presence of a neomycine selection cassette in 
the first intron of the floxed AR allele. The hypomorphic animals 
have reduced testis weights (81% of the control), disturbances in 
the late stages of spermatid differentiation near the time of spermia-
tion, and a reduction in epididymal sperm numbers to 3.9% of nor-
mal. LH and testosterone levels are increased 23-fold and 40-fold 
respectively. Crossing of this floxed strain with an AMH-Cre ex-
pressing strain (distinct from the one used in the two other models) 
results in an inversion of exon 1 selectively in Sertoli cells and a 
further reduction of epididymal sperm numbers to 0.9%. The Sertoli 
cell-selective knockout of the AR in this model (Ar
flox(ex1-neo)/Y
; 
AMH-Cre) is apparently not as complete as in the SCARKO or the 
S-AR
-/y
 as judged by the higher testicular weight (60% of wild-type 
vs. 29%) and the nature of the spermatogenic defect which is situ-
ated at the level of the transition of round to elongating spermatids 
rather than at the level of meiosis. One explanation might be that 
Cre-induced inversion is in principle a reversible reaction. 
5.2.3. Lessons from Sertoli Cell-Selective Knockout Models 
 The main lesson from all three Sertoli cell-selective AR knock-
out models is that they demonstrate, for the first time unambigu-
ously, that the Sertoli cell is the key target of androgen action in the 
control of spermatogenesis. Moreover, both the SCARKO and the 
S-AR
-/y
 suggest that – at least as far as progression through meiosis 
is concerned - the classical AR is the main mediator involved and 
that alternative signaling pathways bypassing this receptor play no 
or only a minor role. In fact, the defect in germ cell development 
observed in the SCARKO and the S-AR
-/y
 is as severe, or even 
more severe, than the defect observed in a number of models in 
which testosterone levels in the testis are drastically reduced such 
as rats treated with silastic implants releasing low doses of testos-
terone and estradiol [3] or mice in which the gene encoding the -
subunit of LH [108] or the gene encoding the LH receptor [109-
111] is inactivated. Finally, both the SCARKO and the S-AR
-/y
 
model stress that progression through meiosis is critically depend-
ent on androgen action. Recent research has mainly emphasized 
conversion of round into elongated spermatids [2, 3, 29-33] and 
spermiation [12, 34, 35] as targets that are particularly sensitive to 
androgen action. Effects of androgens on meiotic progression have 
been observed, however, in many models in which gonadotropins 
were reduced to undetectable levels by hypophysectomy, or by 
pharmacological means [112-114], or in which LH [108] or the LH 
receptor [109-111] were more specifically inactivated. In most of 
these models spermatogenesis proceeds to the pachytene spemato-
cyte level and administration of androgens induces completion of 
meiosis and formation of spermatids. A particularly relevant model 
is the hpg mouse in which spermatogenesis is also arrested at the 
pachytene spermatocyte stage and in which treatment with testos-
terone restores qualitatively normal spermatogenesis and fertility in 
the absence of measurable levels of FSH [18, 19]. Detailed dose-
response studies in this model reveal that progression through 
meiosis requires doses of testosterone that are lower than those 
needed to allow conversion of round into elongated spermatids 
[18]. The observation that spermatid development rather than pro-
gression through meiosis is affected in the Ar
flox(ex1-neo)/Y
; AMH-Cre 
model is also compatible with the hypothesis that lower levels of 
androgen action may be sufficient to allow completion of meiosis.  
 The Sertoli cell-selective knockout models also indicate that 
some effects of androgens on the testis do not depend on the Sertoli 
cell AR. It is apparent for instance that the Sertoli cell AR is not 
required for normal testicular descent in the scrotum. Along the 
same lines and as discussed above, the effect of androgens on the 
proliferation of Sertoli cells does not require an active AR in Sertoli 
cells and may be mediated via neighbouring androgen target cells 
such as the peritubular myoid cells. Gene expression studies sug-
gest that also other Sertoli cell activities such as expression of trans-
ferrin mRNA may depend at least in part on such an indirect path-
way [103]. The contention that peritubular myoid cells may modu-
late or even mediate some effects of androgens on Sertoli cells and 
spermatogenesis is supported not only by in vitro data mentioned 
earlier [75, 76, 78, 90, 115] but also by the recent demonstration 
that animals with a knockout of the AR in peritubular cells display 
a reduction in testis size and oligozoöspermia [116]. Some caution 
may be needed in the interpretation of the data on this peritubular 
AR knockout, however, since the construct used to target Cre ex-
pression to peritubular myoid cells has also been shown to induce 
Cre expression in other cells such as vascular smooth muscle cells 
[117].  
 Finally, the SCARKO model also yields some interesting in-
formation with respect to Leydig cell development. Earlier experi-
ments have demonstrated that the development of the adult genera-
tion of Leydig cells is completely blocked in mice with a ubiquitous 
inactivation of the AR [98, 100, 107]. SCARKO mice develop adult 
Leydig cells as shown by the normal or even increased expression 
of typical markers such as insulin-like factor-3 and estrogen sul-
fotransferase. Nonetheless, a decrease in the number of Leydig cells 
is evident from day 20 onwards. Functionally, this decrease seems 
to be largely compensated by Leydig cell hyperplasia [107]. Taken 
together these data suggest that Leydig cell development not only 
requires direct actions of androgens on developing Leydig cells [98, 
118] but also indirect signals most likely mediated by androgen-
regulated paracrine factors derived from Sertoli cells. These obser-
vations are reminiscent of earlier in vitro [119, 120] and in vivo 
experiments [121, 122] showing that FSH also stimulates Leydig 
cell development via paracrine agonists secreted by Sertoli cells. 
The nature of the paracrine mediators responsible for Leydig-
Sertoli cell interaction remains uncertain. The hypotestosteronemia 
observed in the S-AR
-/y
 model has been related to increased expres-
sion of AMH which is known to inhibit the development of the 
adult Leydig cell generation and steroidogenesis [123, 124]. In the 
SCARKO model, however, AMH expression is not increased and 
shows the expected age-related decline [103]. The marked decrease 
in the expression of PDGF-A in the SCARKO testis [107], a growth 
factor known to be involved in Leydig cell development [125], 
suggests that this might be one of the factors involved. 
6. OTHER TRANSGENIC MODELS WITH MUTANT AR 
ALLELES AFFECTING SERTOLI CELL DEVELOPMENT 
AND FUNCTION  
 As described above, natural variations in the length of the 
CAG/polyglutamine repeat in the amino-terminal part of the human 
AR may affect AR activity, fertility and responsiveness to contra-
ceptive treatment [42]. Moreover, pathological expansion of the 
length of this repeat (> 37) causes a motor neuron disease (SBMA) 
also accompanied by signs of androgen insensitivity, reduced fertil-
ity and testicular atrophy [43]. Two transgenic mouse models have 
been developed that shed some more light on the testicular effects 
of these increased repeat lengths. In the first model a full length 
human AR carrying 120 CAG repeats was over-expressed ubiqui-
tously [126]. A decrease in daily sperm production was observed in 
the presence of normal levels of testosterone, LH and FSH. The 
defect was suggested to be due to a toxic gain of function of the 
mutated protein rather than to a loss of function since such a loss 
would likely have been corrected for by the endogenous mouse AR. 
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In the second study, a knockin mouse model was developed in 
which a 113 CAG repeat was inserted in the mouse AR [127]. The 
mutant AR allele resulted in a progressive disturbance of germ cell 
maturation, decreased testis weight and infertility from the age of 
10 weeks onwards. Immunostaining for -tubulin revealed marked 
disturbances in the Sertoli cell cytoskeleton coinciding with or pre-
ceding the development of the testicular pathology. Quantitative 
RT-PCR for different marker genes of germ cell development indi-
cated a diminished ability of Sertoli cells to support postmeiotic 
germ cells rather than a complete block in meiosis as observed in 
Tfm mice. A partial androgen insensitivity syndrome was suggested 
by the combination of normal testosterone levels and markedly 
increased LH levels as well as by the decreased production of male 
urinary proteins (MUP), a family of androgen-regulated pheromone 
binding proteins produced by the liver. The fact that testicular 
Rhox5/Pem expression in the knockin was as high as in the wild-
type, however, and the decreased solubility of the mutant AR in 
protein lysates of the testis again suggest that the disturbances in 
Sertoli cell function reflect a toxic effect related to the expanded 
glutamine repeat rather than to a loss of function of the AR.  
 Some mutations in the AR gene have been shown to cause 
spermatogenic disturbances without altering the phenotype or ex-
ternal genitalia of the affected infertile men, and even without caus-
ing changes in LH and testosterone levels, suggesting that such 
mutations interfere with specific downstream actions that affect 
spermatogenesis but not LH secretion [42]. A similar dissociation 
of AR downstream effects is observed in the recently described 
SPARKI (Specificity-affecting AR KnockIn) mouse model [128].  
 The SPARKI mouse was developed to test whether classical 
AREs (that are unable to distinguish between the AR and the GR) 
and selective AREs (that supposedly only recognize the AR) acti-
vate different subsets of genes in vivo as they seem to do in vitro 
[47]. To this end the wild-type AR was replaced by a mutant allele 
in which the second zinc-finger is replaced by the second zinc-
finger of the GR resulting in a chimaeric protein that retains the 
ability to bind classical AREs but is unable to bind selective AREs 
(Fig. 1D). SPARKI mice display a unique phenotype reflecting a 
form of androgen insensitivity that is not only partial but also selec-
tive (Table 2). Males carrying the SPARKI allele show normal male 
development and differentiation and their growth curve coincides 
with that of normal males, suggesting that selective AREs are not 
essential for the anabolic effects of androgens. Whereas testoster-
one and LH levels are markedly increased in Ar
flox(ex1-neo)/Y
 mice 
[93], a model of partial androgen insensitivity due to a ubiquitous 
reduction in AR levels (see above), the levels of the same hormones 
are normal in the SPARKI suggesting normal androgen responsive-
ness of the hypothalamic-pituitary feedback system. The testis 
weight of the SPARKI is decreased to 67% of wild-type and the 
ventral prostate and seminal vesicles are also reduced in size (to 54 
and 55% respectively), implying a role of selective AREs in the 
androgen control of these tissues. The reduction in testis weight can 
largely be accounted for by a reduction in the number of Sertoli 
cells (to 68%) but there is also a limited decrease in the ability of 
these Sertoli cells to support germ cell maturation. In fact, the num-
ber of spermatogonia and spermatocytes per Sertoli cell is normal 
but the number of round and elongated spermatids per Sertoli cell is 
reduced to 71 and 68% respectively. SPARKI males display normal 
mounting behaviour and remain fertile but both the number of lit-
ters produced and the size of these litters are reduced by about 50%. 
On day 10, the expression of Rhox5, a typical gene that depends on 
a selective ARE, is reduced by 95% whereas the expression of 
genes that are supposedly controlled by classical AREs (Eppin, 
PCI) is apparently not, or only marginally, affected. The fact that 
anabolic effects of androgens and pituitary feedback regulation 
seem not to be affected in the SPARKI whereas both the testes and 
the accessory sex tissues are reduced in size, suggests that not only 
individual genes but also different physiological programs may be 
affected by targeting either classical or selective AREs. These ob-
servations further support the contention that it may be possible to 
develop selective androgen receptor modulators (SARMS) targeting 
selective subsets of genes and minimizing unwanted side effects 
[129].  
7. THE MOLECULAR PATHWAYS BY WHICH ANDRO-
GENS CONTROL GERM CELL DEVELOPMENT 
 After the establishment of the Sertoli cell as the main target for 
androgen action in the control of spermatogenesis the main chal-
lenge remains to unravel the molecular pathways involved. Since, 
as already discussed, studies with isolated Sertoli cells or Sertoli 
cell lines have proven of limited help, recent attempts have focused 
on the use of in vivo sytems. Such studies have been made possible 
by the development of a number of powerful experimental models 
and tools. Mice with a selective ablation of the AR in Sertoli cells 
certainly represent one of the most interesting experimental para-
digms presently available. Essentially two approaches are possible 
in the search for androgen-regulated genes relevant to spermato-
genesis. One possibility is to depart from a process known to be 
dependent on androgen action (meiosis, spermatid adhesion, sper-
Table 2. Comparison of the Phenotypes of Mouse Strains Expressing Different AR Alleles in A Ubiquitous or A Sertoli Cell-Selective Fashion 
 AR
flox
 day 50 SCARKO day 50 ARKO day 50 SPARKI day 77 
AR allele Floxed exon 2 Deletion of exon 2 Deletion of exon 2 Substitution of exon 3 by GR exon 4 
Expression of mutant allele ubiquitous Sertoli cell ubiquitous ubiquitous 
External phenotype male male female male 
Development of male reproductive tract normal normal absent normal 
Testicular descent normal normal defective normal 
Testis weight 86% * 28% * 8% * 67% * 
Seminal vesicle weight 106% 108% absent 55% * 
Body weight curve male male female male 
Serum LH 71% 178% 1435% * 113% 
Serum FSH 123% 129% * 145% * 103% 
Sertoli cell number  109% 97% 43%* 68%* 
Total GC  93% 28% * 3% * 55% * 
Quantitative values are expressed as a percentage of the control. Values that differ significantly (P<0.05) are indicated by an asterisk. 
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miation…) and to explore directly which of the genes involved may 
be subject to androgen regulation. Alternatively, microarray tech-
nology can be used to screen genome wide for genes that are af-
fected by the presence/and or activity of androgens in the testis or 
in Sertoli cells. The latter approach has recently revealed some 
intriguing properties of the androgen-regulated gene network in the 
testis and in this overview we will focus on these microarray data.  
 The first two studies applying microarray technology to the 
study of androgen action in the testis concentrated on early effects 
of androgens in either hpg mice or wild-type prepubertal mice [130, 
131]. The use of exogenous androgens implies that the observed 
effects may reflect primary actions in Sertoli cells, Leydig cells or 
peritubular myoid cells.  
 In the hpg model early effects of testosterone propionate (TP 25 
mg sc) were analyzed in males pretreated or not with TP. Pretreat-
ment consisted of 3 injections of 5 mg TP every other day followed 
by 14 days without treatment [130]. One of the most intriguing 
observations was that at all time points earlier than 24 h after the 
final TP injection, more mRNAs were reduced in abundance rather 
than increased. Some of the more intriguing down-regulated tran-
scripts included nuclear protein 220 and matrin 3, encoding nuclear 
proteins that might play a role in pre-mRNA splicing, and some 
class 1 major histocompatibility genes including H2-D1. In the up-
regulated transcripts transient but marked up-regulation was ob-
served at 4 h for several transcripts encoding major milk proteins 
(casein-, - and - and whey acidic protein). Rhox5 expression 
was increased from 8 h after treatment onwards.  
 The study on 8-day-old wild-type mice compared early effects 
(4-16 h after treatment) of TP or DHT (0.5 mg) [131]. No differ-
ences were noticed, however, between the effects of the aromatiz-
able androgen T and its non-aromatizable metabolite DHT. The 
expression of some 200 genes was found to be modulated 2-fold or 
more by TP treatment with an approximately equal distribution 
between up-regulated and down-regulated genes. Comparison with 
androgen-regulated genes in the hpg model revealed only a few 
similarities including Rhox5 and Cyp171 (cytochrome P450 17-
hydroxylase/17, 20-lyase), a Leydig cell gene down-regulated by 
TP. Among the interesting genes identified was Amotl1 (angio-
motin-like 1), a gene that encodes a tight junction protein with con-
served coiled-coil and PDZ-binding domains which seems to be up-
regulated by TP, and StAR, a gene that encodes a carrier that trans-
ports cholesterol to the inner mitochondrial membrane and that is 
down-regulated by TP not only in Leydig cells but also in Sertoli 
cells.  
 Two studies have searched for testicular genes that are differen-
tially expressed in mice with a Sertoli cell-selective knockout of the 
AR compared to control animals and one study has tried to identify 
tubular and somatic genes differentially expressed in mice with a 
ubiquitous inactivation of the AR (Tfm) [132-134].  
 A first study compared testicular gene expression in SCARKO 
and control male littermates on postnatal day 10 [132]. This time 
point was selected to avoid confounding effects of differences in 
testicular (germ) cell composition due to the meiotic block in 
SCARKO testes. Moreover, on day 10 the AR is clearly present in 
Sertoli cells of control testes (in line with earlier studies demon-
strating expression of Rhox5 in wild-type testes from day 9 on-
wards [86]). Statistical analysis of microarray data from five inde-
pendent samples from SCARKO and control testes revealed differ-
ential expression of 692 genes (396 down-regulated in the 
SCARKO and 296 up-regulated). Only 40 of the identified genes, 
however, showed a difference in expression of at least 2-fold (28 
down-regulated and 12 up-regulated in the SCARKO). Genes 
down-regulated in the SCARKO supposedly depend on androgen 
action in Sertoli cells for their normal expression. Interestingly, at 
least 3 of these genes (Galgt1 (-1,4-Acetylgalactosaminyl- 
transferase), PCI (protein C inhibitor) and Eppin (a serine protease 
inhibitor)) were shown to be essential for male fertility by previous 
knockout or inactivation studies, and for at least 5 of them (Rhox5, 
Eppin, Gpd1 (Glycerol-3-phosphate dehydrogenase 1), Tubb3 (Tu-
bulin-3), Tpd52l1 (Tumor protein D52-like) and PCI) there were 
earlier indications of androgen regulation. Preferential expression in 
the tubular compartment and sensitivity to treatment with anti-
androgens could be confirmed for 9 genes studied by quantitative 
RT-PCR: Rhox5, Eppin, Galgt1, Drd4 (dopamine receptor 4), Tsx 
(Testis specific X-linked gene), Gpd1, Tubb3, PCI, Tpd52l1. Rhox5 
turned out to be the gene displaying the largest difference between 
SCARKO and control. Functions overrepresented in the 396 down-
regulated genes included MAPK activity and, perhaps most strik-
ingly, serine-type endopeptidase inhibitor activity with 5 of these 
inhibitors down-regulated more that 2-fold. Functions overrepre-
sented in the 296 genes up-regulated in the SCARKO included: 
signal transduction, cell adhesion, Ca
++
-binding, Ca
++
-dependent 
phospholipid binding and IGF binding. A time study (day 8-20) 
confirmed the observed pattern of differential expression and also 
indicated that, apart from serine-type endopeptidase inhibitors and 
cell adhesion molecules, also serine proteases and genes encoding 
cytoskeletal elements and extracellular matrix components dis-
played early and important differences in expression; this suggests 
that tubular restructuring and cell-junction dynamics may be proc-
esses targeted by androgens during prepubertal and early pubertal 
development.  
 In a second study, transcriptional profiling was performed to 
search for differentially expressed genes in the Ar
flox(ex1-neo)/Y
; 
AMH-Cre model [93, 133]. Since, in this case, the floxed males 
already display partial androgen insensitivity and a hypomorphic 
phenotype, the study also tried to identify genes specifically or 
preferentially affected in the testes of hypomorphic animals, genes 
affected both in hypomorphic mice and in mice with a Sertoli cell-
selective knockout and genes specifically or preferentially affected 
in the Sertoli cell-selective knockout. A major difference with the 
SCARKO study is that microarray analysis was performed at the 
age of 8 weeks. The expression of 62 transcripts was found to differ 
by greater than 2-fold in the testes of AR mutants as compared to 
wild-type and more transcripts were up-regulated than down-
regulated. Functions that were predominant in the genes differen-
tially expressed in the mutants related to metabolic processes, sig-
nal transduction and proteases. Twelve transcripts were identified 
that were uniquely affected in the Sertoli cell-selective knockout 
and 16 were more affected in the cell-selective knockout than in the 
hypomorph. None of these genes corresponded to those affected 
more than 2-fold in the SCARKO model. Actually the only com-
mon gene picked up in the 2 studies was Rhox5 (down regulated 
18-fold in the SCARKO and 2-fold in the hypomorph and in the 
Ar
flox(ex1-neo)/Y
; AMH-Cre). The lack of common transcriptional 
changes between the two studies can largely be explained by differ-
ences inherent to the models and differences in experimental setup. 
As discussed earlier the SCARKO model probably represents a 
more Sertoli cell-selective and a more complete inactivation of the 
AR. Since spermatogenesis is blocked in meiosis this model pro-
vides valuable information on androgen-regulated genes needed to 
initiate and support meiosis. Potential effects of androgens specifi-
cally related to postmeiotic events in germ cell development, how-
ever, may go unnoticed. Such effects may be picked up in the Ar-
flox(ex1-neo)/Y
; AMH-Cre model since postmeiotic germ cell develop-
ment is observed there. Furthermore, the decision in the SCARKO 
study to search for genes differentially expressed on day 10 has the 
important advantage that it avoids confounding effects on Sertoli 
cell or somatic cell gene expression by differences in germ cell 
development between mutant and control. As illustrated for two 
representative genes in Fig. 2 this may be an important confounding 
factor. While microarray data suggests a decrease in the differential 
expression of Rhox5 and a complete loss of differential expression 
for PCI on day 20, quantitative RT-PCR shows that this is an arti-
fact caused by the increased contribution of germ cells to the total 
10 Immun., Endoc. & Metab. Agents in Med. Chem., 2008, Vol. 8, No. 1 Verhoeven et al. 
RNA in the control. A drawback of studies on day 10 is of course 
that Sertoli cells are still immature and proliferating and that some 
effects of androgens that depend on the presence of more mature 
germ cells may not be observed. An additional confounding factor 
inherent to the Ar
flox(ex1-neo)/Y
; AMH-Cre model is the 25-fold in-
crease in LH that is already evident in the floxed mice. This in-
crease may explain the observed up-regulation of several known 
targets of LH signaling in the AR mutants.  
 A third study compared gene expression in the testes of 20-day-
old Tfm and control mice. Initially some 4700 differentially ex-
pressed genes were identified most of them of germ cell origin 
[134]. Subsequent in silico screening and comparison with gene 
expression data of mice treated with busulphan to cause depletion 
of germ cells and with W
v
/W
v
 mice lacking germ cells because of a 
mutation in the c-kit receptor, identified 20 genes of a somatic tubu-
lar origin that were significantly down-regulated in the Tfm testis 
and 6 genes that were significantly up-regulated. For nearly all of 
these genes differential expression was confirmed by quantitative 
RT-PCR and for 14 of them down-regulated in the Tfm testis, up-
regulation by androgens could be confirmed in hpg mice treated for 
1 week with a testosterone implant. Surprisingly, none of the genes 
up-regulated in the Tfm was affected by androgen treatment in the 
hpg. Of the total number of genes showing differential expression 
in the Tfm testis, 50% were associated with vitamin A metabolism, 
solute transportation and cytoskeletal function leading the authors 
to suggest that androgens may affect spermatogenesis by modulat-
ing the tubular environment, and by control of retinoic acid metabo-
lism.  
 Although Rhox5 is the only differentially expressed gene iden-
tified in the 3 AR knockout studies, as well as in the other two tran-
scriptional profiling studies, there may be some other similarities 
that should be mentioned and that merit further investigation. Sev-
eral genes related to retinoic acid metabolism were identified in the 
Tfm model as well as in the hypomorph and the Ar
flox(ex1-neo)/Y
; 
AMH-Cre. Alcohol dehydrogenase 1 (class 1), the rate limiting 
enzyme in the conversion of vitamin A to the potent signaling 
molecule retinoic acid, was even found to be upregulated more that 
10-fold in both studies, raising the intriguing possibility of a cross-
talk between androgen signaling and the retinoic acid pathway. 
Examination of the larger lists of genes that are differentially ex-
pressed, revealed that 59 genes are down-regulated and 169 are up-
regulated both in the SCARKO and the Tfm. Only 7 of these genes 
show a 2-fold or greater difference in both models. These 7 genes 
include: Rhox5, Drd4, low density lipoprotein-related protein 4, 
Tsx and 3 of the serine-type endopeptidase inhibitors: Eppin, Ser-
pina 3N and PCI. Cell-adhesion molecules and cytoskeletal ele-
ments were also noticed in the three studies. The tight junction 
component claudin 3, for instance, was found to be specifically 
down-regulated in the Ar
flox(ex1-neo)/Y
; AMH-Cre and was also down-
regulated in the SCARKO from the age of 14 days onwards. Its 
down-regulation correlates with disturbance of formation of the 
blood-testis barrier observed in the Ar
flox(ex1-neo)/Y
; AMH-Cre [135]. 
This barrier is also disturbed in the Tfm [136] and the specific con-
tribution of the Sertoli cell and claudin 3 to this disturbance war-
rants further investigation.  
8. MAIN CONCLUSIONS FROM THE AVAILABLE GENE 
PROFILING STUDIES 
 While transcriptional profiling studies on intact testis tissue 
avoid the loss of differentiated function and androgen responsive-
ness observed in isolated and cultured Sertoli cells, they are obvi-
ously subject to a number of inherent limitations: the cellular origin 
of differentially expressed transcripts is not immediately evident; 
differences in cellular composition between experimental samples 
and controls may confound the interpretation of the data, and for 
transcripts that are expressed in different cell types, changes in 
expression in one cell type may go unnoticed by the absence of 
such changes or by opposite changes in the other cell types. There 
is obviously a need for a more detailed analysis of the existing data 
and for careful additional work. Nonetheless, and despite the poor 
level of correspondence between the available data, some tentative 
conclusions may be appropriate. 
1) All studies, even those looking at very early effects (4-24 h), 
identify relatively large sets of genes that may be regulated ei-
ther directly or indirectly by androgens in the testis. This sug-
gests that androgens may affect an entire spectrum of genes 
rather than a few key genes. In most of the available data sets 
the cells responsible for the expression of the alleged androgen 
target genes have only tentatively been identified. Moreover, 
the number of genes for which differential expression has been 
confirmed by an alternative technique such as quantitative RT-
PCR remains limited. Finally it remains to be defined which 
genes are primary and which genes are secondary response 
genes. 
2) The fact that Rhox5, a gene known to be induced up to 50-fold 
by direct interaction with the activated AR in Sertoli cells, is 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Expression patterns of the Rhox5 [128] and the PCI (Protein C Inhibitor) gene between day 6 and 20. Gene expression was assessed by microarray 
analysis and quantitative RT-PCR (Q-RT-PCR). Left axis [152]: Expression levels measured by Q-RT-PCR in testes of control and SCARKO mice of the 
indicated ages (n=3). Data were normalized to an external luciferase standard. All values are expressed as a percentage of the highest value measured for the 
corresponding gene arbitrarily set at 100. Values represent the mean ± SEM of 3 measurements. Right axis (lines): Gene expression measured by microarray 
analysis on a pool of mRNA from 3 testes of 3 control or SCARKO mice of the indicated ages. Data are expressed as a percentage of the highest signal ob-
served for the studied gene arbitrarily set at 100. 
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identified in all the reported studies, despite the widely different 
experimental approaches used, proves that all these studies have 
the power to identify strongly regulated androgen target genes 
in Sertoli cells. As a consequence, the finding that there is not a 
single other gene that is consistently picked up in the same 
studies may indicate either that Rhox5 is the only gene display-
ing such an important degree of regulation, or that other 
strongly regulated genes are expressed only transiently or that 
relevant genes may not be included in routinely available mi-
croarrays. The prominent presence of Rhox5 in all studies 
makes it surprising that disruption of Rhox5 has only limited ef-
fects on germ cell development and fertility. This may in part 
be explained by the recent finding that Rhox5 is a member of a 
class of at least 12 homeobox genes and, accordingly, that a 
loss in function of Rhox5 may be partially compensated for by 
some of the other members of the Rhox family [84]. Further 
studies on these Rhox genes and their orthologs in other species 
are obviously required. 
3) Given the widely different experimental approaches and their 
specific advantages and limitations, the resulting data should be 
regarded as complementary rather than as contradictory. Keep-
ing all the mentioned restrictions in mind, it cannot be ignored 
that the summarized studies have greatly expanded the pool of 
putative testicular androgen target genes and provide a firm ba-
sis for hypothesis-driven research. Along these lines it is impor-
tant to note that some genes and functions are overrepresented 
or at least prominently present in the available sets of data.  
 We already mentioned that 2 studies identified several genes  
related to vitamin A metabolism suggesting a link between an- 
drogen action and retinoic acid metabolism. Such a link might  
be highly relevant given the increasing evidence for a role of  
retinoic acid in the control of meiosis [137, 138]. Interestingly,  
both studies involved animals with a ubiquitous (complete or  
partial) form of androgen insensitivity, suggesting that Sertoli  
cells might not be the main or the only cell involved.  
 Other gene products found to be markedly modulated by andro-
gen action in several of the summarized studies are proteases 
and protease inhibitors, cell adhesion molecules and cytoskele-
tal elements, suggesting that tubular restructuring (related to 
pubertal development and/or germ cell migration) and cell junc-
tion dynamics may be important targets for androgen action. By 
controlling tubular restructuring and cell junction dynamics as 
well as cell metabolism and important carriers involved in sol-
ute transportation, functions that are also prominently present in 
several studies, androgens may play a key role in the creation of 
an environment that is permissive for germ cell development. 
4) The available list of putative target genes offers a basis to 
screen for genes that are also androgen regulated in other mod-
els and species and in this way to develop tools to study dis-
turbed androgen action in experimental animals and in man. 
Androgen-regulated genes identified in the SCARKO model, 
for example, have proven useful to guide searches in the 
SPARKI model for genes that depend on selective or classical 
AREs [128]. 
9. GENERAL CONCLUSIONS AND PERSPECTIVES FOR 
MALE CONTRACEPTION 
 The development of novel transgenic models and the introduc-
tion of transcriptional profiling have allowed considerable progress 
in our understanding of androgen action in the testis. Sertoli cell-
selective knockout models show unambiguously that the Sertoli cell 
is the key target for androgen action in the control of spermatogene-
sis. An intriguing but essential property of the Sertoli cell is that its 
androgen responsiveness, as well as the nature of its responses, is 
variable and markedly influenced by its microenvironment and its 
interactions with neighboring peritubular and germ cells. Compari-
son of mice with ubiquitous and Sertoli cell-selective knockouts of 
the AR as well as studies in mice with a peritubular cell AR knock-
out indicate that peritubular myoid cells contribute to some specific 
effects of androgens on Sertoli cells and spermatogenesis. The na-
ture of the signaling pathways involved remains largely elusive. 
Mice with a complete and selective knockout of the AR in Sertoli 
cells show that progress through meiosis is critically dependent on 
activation of the AR in Sertoli cells. There are several indications 
that meiosis requires lower concentrations of androgens than subse-
quent steps in the spermatogenic cascade and, accordingly, identifi-
cation of androgen-dependent genes controlling progression 
through meiosis is central to our understanding of the regulation 
and molecular basis of androgen-driven induction of spermatogene-
sis. The finding that higher levels of androgen stimulation may be 
needed for some postmeiotic steps in germ cell development leaves 
the possibility that other androgen-induced mediators and/or alter-
native signaling pathways may be involved.  
 A few mouse models have been developed mimicking human 
diseases in which mutations of the AR cause disturbed fertility 
without affecting male sexual development. Male mice expressing 
an AR with an expanded CAG/polyglutamine repeat display a pro-
gressive form of subfertility comparable to that observed in SBMA 
and offer a paradigm to study the mechanisms by which this AR 
polyglutamine tract results in toxicity in Sertoli cells. The SPARKI 
mouse shows that androgen-responsive genes can be differentially 
targeted depending on the nature (classical or selective) of their 
AREs. Selective AREs are apparently not essential for the anabolic 
effects of androgens and pituitary feedback but are important for 
their reproductive functions and more particularly for the numerical 
and functional development of Sertoli cells and for fertility. The 
model suggests that it should be possible to target particular subsets 
of genes (e.g. related to fertility) while minimizing effects on other 
subsets.  
 Transcriptional profiling studies in mice with Sertoli cell-
selective AR ablation, and in a number of other experimental para-
digms, have tried to identify androgen-regulated genes relevant to 
the control of spermatogenesis. In all studies, relatively large num-
bers of genes, rather than a few key genes, seem to be affected by 
androgen action although the number of genes affected 2-fold or 
more is more limited. Nonetheless, apart from Rhox5, there is little 
overlap in the lists of genes that have tentatively been identified as 
androgen regulated and/or expressed in Sertoli cells. This may be 
due largely to dissimilarities in experimental setup and to inherent 
differences in the experimental paradigms used for gene identifica-
tion. There is an obvious need for a critical appraisal of the genes 
presently identified and for further studies. Genes related to tubular 
restructuring, cell junction dynamics, cytoskeleton, solute transpor-
tation and vitamin A metabolism are prominently present in the 
available data sets. All these processes have been shown to be ame-
nable to pharmacologic interference and/or to be targets for toxic 
effects on spermatogenesis [139-141]. It is obvious, however, that 
more work is needed to identify androgen-dependent target genes 
that could serve as a suitable base for novel forms of male contra-
ception. Ideal targets should: 1) be expressed and exert critical 
functions (also) in the adult human testis; 2) be amenable to testing 
in animals; 3) not produce adverse effects other than male infertility 
when inactivated. Testis-specific target genes expressed in Sertoli 
cells, rather than in germ cells, have an obvious attraction since 
they may avoid the need to pass through the blood-testis barrier. 
Interference with androgen target genes playing a key role in the 
control of spermatogenesis (rather than with androgen production 
itself, as in current contraceptive regimens) would offer the impor-
tant advantage that it avoids the need for androgen administration 
with all the inherent problems of reaching optimal concentrations 
and a correct balance between androgens and their metabolites. One 
of the important lessons from the mice models with a Sertoli cell-
selective knockout of the AR may be that they show that it is possi-
ble to interfere with androgen signaling and to block spermatogene-
12 Immun., Endoc. & Metab. Agents in Med. Chem., 2008, Vol. 8, No. 1 Verhoeven et al. 
sis completely without causing a massive breakdown of testicular 
architecture or major inflammatory reactions. 
 In conclusion: although further work needs to be done, it may 
reasonably be anticipated that continued efforts to identify andro-
gen-regulated genes in the testis will result in the identification of 
subsets of genes that can be used for diagnostic purposes and in the 
identification of targets for the development of novel male 
contraceptives. 
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